INNOVATIVE IMPLANTABLE GLUCOSE BIOSENSOR

Not Available Building on its previous SBIR success, Eikos LLC has assembled a team of researchers that is the best qualified in the world to carry out a P. falciparum microarray fabrication project. This effort will incorporate Eikos's large sequence database and develop bioinformatics tools to enhance the utility of these microarrays. The Phase I program described in this proposal will lead to the fabrication of a resistance genotype micorarray. More importantly, it will establish procedures for rapid prototyping of falciparum microarrays which will be very important as more genomic data for Plasmodium species becomes known. The proposed Phase I effort will support the Phase II effort by reducing to practice the techniques needed to develop microarrays for malaria from genomic databases. BENEFITS: Malaria microarrays will enable the diagnosis and surveillance of drug resistant strains, protecting the international community at large. This technology also supports the development of antimalrial drugs which are needed across the Globe.